Seminars in Hematology
Volume 43, Issue 1 , Pages 42-52, January 2006

The Lung as a Target Organ of Graft-Versus-Host Disease

  • Gregory Yanik
  • ,
  • Kenneth R. Cooke

      Affiliations

    • Corresponding Author InformationAddress correspondence to Kenneth R. Cooke, MD, Assistant Professor of Pediatrics–Hematology/Oncology, University of Michigan Medical School, 1500 E Medical Center Dr, 6306 CCGC, Ann Arbor, MI 48109-0942

Department of Pediatrics, Division of Hematology/Oncology, Blood and Marrow Transplantation Program, University of Michigan Cancer Center, Ann Arbor, MI

Despite significant advances in critical care and transplantation medicine, non-infectious lung injury remains a major problem following allogeneic hematopoietic stem cell transplantation (HSCT) both in the immediate post-transplant period and in the months to years that follow. Historically, approximately 50% of all pneumonias seen after HSCT have been secondary to infection. Although non-infectious lung injury occasionally occurs following autologous transplants, the allogeneic setting greatly exacerbates toxicity acutely and chronically. Pulmonary injury is associated with significant morbidity and mortality and responds poorly to standard therapies. Insights generated using animal models suggest that the immunologic mechanisms contributing to lung inflammation after HSCT may be similar to those responsible for graft-versus-host disease (GVHD).

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 K.R.C. is an Amy Strelzer-Manasevit Scholar of the National Marrow Donor Program, a Fellow of the Robert Wood Johnson Minority Faculty Development Program, a Leukemia and Lymphoma Society Scholar in Clinical Research and the recipient of a Clinical Scientist Award in Translational Research from the Burroughs Wellcome Fund.

PII: S0037-1963(05)00170-8

doi:10.1053/j.seminhematol.2005.09.004

Seminars in Hematology
Volume 43, Issue 1 , Pages 42-52, January 2006